Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Thursday. $139.96 million flowed into the stock on the tick-up and $350.26 million flowed out of the stock on the tick-down, for a money net flow of $210.30 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 5th highest net out-flow for the day. Johnson & Johnson traded up $1.05 for the day and closed at $129.09

A number of equities analysts have commented on JNJ shares. Citigroup reduced their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price for the company in a report on Wednesday, December 12th. Morgan Stanley set a $140.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, Credit Suisse Group increased their target price on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $140.27.

The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. The firm has a market cap of $347.06 billion, a P/E ratio of 17.68, a P/E/G ratio of 1.91 and a beta of 0.72.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be issued a $0.90 dividend. The ex-dividend date of this dividend is Monday, February 25th. This represents a $3.60 annualized dividend and a dividend yield of 2.79%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

Johnson & Johnson announced that its board has approved a stock repurchase plan on Monday, December 17th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 1.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

In other Johnson & Johnson news, insider Joaquin Duato sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the completion of the sale, the insider now owns 112,848 shares of the company’s stock, valued at $16,290,737.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 8,441 shares of the firm’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total value of $1,225,211.15. Following the sale, the chief accounting officer now directly owns 17,284 shares of the company’s stock, valued at approximately $2,508,772.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 514,187 shares of company stock valued at $74,951,528. Insiders own 0.22% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after buying an additional 3,235,861 shares during the period. Vanguard Group Inc boosted its position in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after buying an additional 3,235,861 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 1.3% during the third quarter. Bank of New York Mellon Corp now owns 33,892,560 shares of the company’s stock worth $4,682,935,000 after buying an additional 435,564 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Johnson & Johnson by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after buying an additional 541,338 shares during the period. Finally, Morgan Stanley boosted its position in shares of Johnson & Johnson by 6.3% during the third quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock worth $3,166,921,000 after buying an additional 1,352,484 shares during the period. 66.20% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.com-unik.info/2019/01/17/traders-sell-johnson-johnson-jnj-on-strength-jnj.html.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: Analyst Ratings Trading

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit